Bladder cancer is the sixth most commonly diagnosed cancer in the European Union. Here, we evaluate the performance of a novel, commercially available enzyme-linked immunosorbent assay utilising MCM5 antibodies (ADXBLADDER; Arquer Diagnostics Ltd, Sunderland, UK) for the detection of bladder cancer, in a blinded, prospective study of 856 patients, across seven centres, presenting with haematuria. 

European Urology Oncology. 2019 Jul 12 [Epub ahead of print]

Tim Dudderidge, Jacqui Stockley, Ghulam Nabi, Jaswant Mom, Nkemi Umez-Eronini, David Hrouda, Jo Cresswell, Stuart Robert Crozier McCracken

https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/113945-a-novel-non-invasive-test-enabling-bladder-cancer-detection-in-urine-sediment-of-patients-presenting-with-haematuria-a-prospective-multicentre-performance-evaluation-of-adxbladder.html